143 related articles for article (PubMed ID: 30429706)
1. Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis.
Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
Postepy Dermatol Alergol; 2018 Oct; 35(5):485-489. PubMed ID: 30429706
[TBL] [Abstract][Full Text] [Related]
2. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
[TBL] [Abstract][Full Text] [Related]
3. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.
Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
Mediators Inflamm; 2017; 2017():9538451. PubMed ID: 28932021
[TBL] [Abstract][Full Text] [Related]
4. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40.
Ataseven A; Kesli R
G Ital Dermatol Venereol; 2016 Jun; 151(3):244-50. PubMed ID: 25279492
[TBL] [Abstract][Full Text] [Related]
5. Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings.
Ahmed SF; Attia EA; Saad AA; Sharara M; Fawzy H; El Nahrery EM
J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):682-8. PubMed ID: 25087779
[TBL] [Abstract][Full Text] [Related]
6. Serum YKL-40 as a potential biomarker of inflammation in psoriasis.
Baran A; Myśliwiec H; Szterling-Jaworowska M; Kiluk P; Świderska M; Flisiak I
J Dermatolog Treat; 2018 Feb; 29(1):19-23. PubMed ID: 28498006
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis.
Kong Y; Zhang S; Su X; Peng D; Su Y
Postgrad Med; 2019 Aug; 131(6):405-412. PubMed ID: 31298974
[No Abstract] [Full Text] [Related]
8. Serum YKL-40 and IL 17 in Psoriasis: Reliability as prognostic markers for disease severity and responsiveness to treatment.
Khashaba SA; Attwa E; Said N; Ahmed S; Khattab F
Dermatol Ther; 2021 Jan; 34(1):e14606. PubMed ID: 33249724
[TBL] [Abstract][Full Text] [Related]
9. [Association of skin lesion severity with clinical features of psoriatic arthritis].
Liu HL; He N; Dou L; Wang YH; Su JM; Li MT; Leng XM; Zeng XF
Zhonghua Nei Ke Za Zhi; 2022 Jul; 61(7):779-784. PubMed ID: 35764561
[No Abstract] [Full Text] [Related]
10. Chitinase-3-like Protein 1 (YKL-40): A New Biomarker of Inflammation in Pyoderma Gangrenosum.
Jankowska-Konsur A; Łyko M; Rubas K; Nowicka-Suszko D; Maj J; Szepietowski JC
Acta Derm Venereol; 2022 Feb; 102():adv00646. PubMed ID: 34935995
[TBL] [Abstract][Full Text] [Related]
11. Galectin-1 in Psoriatic arthritis, Psoriasis, Rheumatoid arthritis and its relation with disease activity and skin lesion.
El Bably MM; Abdel Aziz DM; Adly NN; Ali MA; Khedr AS; El Leithy SA
Egypt J Immunol; 2023 Apr; 30(2):73-82. PubMed ID: 37031409
[TBL] [Abstract][Full Text] [Related]
12. Differences in oxylipin profile in psoriasis versus psoriatic arthritis.
Coras R; Kavanaugh A; Kluzniak A; Holt D; Weilgosz A; Aaron A; Quehenberger O; Ritchlin C; Guma M
Arthritis Res Ther; 2021 Jul; 23(1):200. PubMed ID: 34303373
[TBL] [Abstract][Full Text] [Related]
13. Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy.
Abu El-Hamd M; Adam El Taieb M; Mahmoud AA; Mahmoud Samy O
J Dermatolog Treat; 2019 Sep; 30(6):545-548. PubMed ID: 30482111
[No Abstract] [Full Text] [Related]
14. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis.
Kazakova M; Batalov A; Deneva T; Mateva N; Kolarov Z; Sarafian V
Rheumatol Int; 2013 Feb; 33(2):341-6. PubMed ID: 22451025
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study.
Conrozier T; Carlier MC; Mathieu P; Colson F; Debard AL; Richard S; Favret H; Bienvenu J; Vignon E
Ann Rheum Dis; 2000 Oct; 59(10):828-31. PubMed ID: 11005786
[TBL] [Abstract][Full Text] [Related]
16. The influence of tumour necrosis factor α inhibitors treatment - etanercept on serum concentration of biomarkers of inflammation and cartilage turnover in psoriatic arthritis patients.
Waszczykowski M; Bednarski I; Lesiak A; Waszczykowska E; Narbutt J; Fabiś J
Postepy Dermatol Alergol; 2020 Dec; 37(6):995-1000. PubMed ID: 33603621
[TBL] [Abstract][Full Text] [Related]
17. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
18. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
La Montagna G; D'Angelo S; Valentini G
J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
[TBL] [Abstract][Full Text] [Related]
19. Chitinase-3-Like Protein 1 (YKL-40) Reflects the Severity of Symptoms in Atopic Dermatitis.
Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
J Immunol Res; 2017; 2017():5746031. PubMed ID: 28660216
[TBL] [Abstract][Full Text] [Related]
20. Enthesitis and its relationship with disease activity, functional status, and quality of life in psoriatic arthritis: a multi-center study.
Sunar I; Ataman S; Nas K; Kilic E; Sargin B; Kasman SA; Alkan H; Sahin N; Cengiz G; Cuzdan N; Gezer IA; Keskin D; Mülkoğlu C; Resorlu H; Bal A; Duruöz MT; Küçükakkaş O; Yurdakul OV; Melikoglu MA; Aydın Y; Ayhan FF; Bodur H; Calis M; Capkın E; Devrimsel G; Gok K; Hizmetli S; Kamanlı A; Keskin Y; Kocabas H; Kutluk O; Şen N; Şendur OF; Tekeoğlu I; Tolu S; Toprak M; Tuncer T
Rheumatol Int; 2020 Feb; 40(2):283-294. PubMed ID: 31773391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
